Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study

• Published in: Frontiers in pharmacology Vol. 12; p. 670900
• Main Authors: Sun, Yiting, Jiang, Liqing, Wen, Ti, Guo, Xiaoyu, Shao, Xinye, Qu, Hui, Chen, Xi, Song, Yujia, Wang, Fang, Qu, Xiujuan, Li, Zhi
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 17.08.2021
• Subjects: bibliometrics; immune checkpoint blockade; meta-analysis; PD1/PDL1; Pharmacology; randomized clinical trials
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2021.670900

The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer immunotherapy. The related literature shows the explosive growth trends due to the promising outcomes of tumor regression. The present study aimed to provide a comprehensive bibliometric analysis of the literature on anti-PD1/PDL1 from three perspectives including molecular mechanisms, randomized clinical trials (RCT), and meta-analysis, thus producing a knowledge map reflecting the status of the research, its historical evolution, and developmental trends in related research from 2000 to 2020. We included 11,971, 191, and 335 documents from the Web of Science Core Collection database, respectively, and adopted various bibliometric methods and techniques thereto. The study revealed the major research themes and emergent hotspots based on literature and citation data and outlined the top contributors in terms of journals and countries. The co-occurrence overlay of keywords and terms pertaining to the PD1/PDL1 molecule reflected the progress from the discovery of the PD1/PDL1 molecule to the clinical application of anti-PD1/PDL1. Immune-related adverse events (irAEs) formed a unique cluster in the term co-occurrence analysis of meta-analysis. The historical direct citation network of RCT indicated the development and transformation of cancers and therapy strategies. irAEs and the strategies of combination therapy might become a future focus of research in this cognate area. In summary, the bibliometric study provides a general overview of the landscape on anti-PD1/PDL1 research, allowing researchers to identify the potential opportunities and challenges therein.